Boston Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Boston Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.08M	Buy	17,359 +6,568	+61%	+$412K	0.06%	372
2019 Q2	$768K	Sell	10,791 -8,160	-43%	-$601K	0.04%	416
2019 Q1	$1.49M	Buy	18,951 +9,811	+107%	+$743K	0.08%	266
2018 Q4	$774K	Buy	9,140 +777	+9%	+$82.8K	0.04%	377
2018 Q3	$1.43M	Sell	8,363 -104	-1%	-$15.7K	0.06%	317
2018 Q2	$1.09M	Buy	+8,467	New	+$945K	0.03%	362

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Boston Advisors's LGND Position: Q3 2019 in Review

Boston Advisors increased its Ligand Pharmaceuticals (LGND) stake by 61% in Q3 2019, buying an estimated $412K and bringing the position to 17,359 shares worth $1.08M. The position accounts for 0.06% of the portfolio, ranked #372.

Boston Advisors first reported a position in LGND in Q2 2018 and has held it in 6 quarters since. The position peaked at $1.49M in Q1 2019. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Boston Advisors held 17,359 shares of Ligand Pharmaceuticals worth $1.08M as of Q3 2019.
Boston Advisors bought 6,568 Ligand Pharmaceuticals shares in Q3 2019, an estimated $412K.
Ligand Pharmaceuticals made up 0.06% of Boston Advisors's portfolio in Q3 2019, its #372 holding.
Boston Advisors first reported a position in Ligand Pharmaceuticals in Q2 2018 and has held it in 6 quarters since.
Boston Advisors's Ligand Pharmaceuticals position peaked at $1.49M in Q1 2019.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.